95 related articles for article (PubMed ID: 19623658)
1. Elevated level of 8-oxo-7,8-dihydro-2'-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls.
Dziaman T; Huzarski T; Gackowski D; Rozalski R; Siomek A; Szpila A; Guz J; Lubinski J; Olinski R
Int J Cancer; 2009 Nov; 125(9):2209-13. PubMed ID: 19623658
[TBL] [Abstract][Full Text] [Related]
2. Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers.
Dziaman T; Huzarski T; Gackowski D; Rozalski R; Siomek A; Szpila A; Guz J; Lubinski J; Wasowicz W; Roszkowski K; Olinski R
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2923-8. PubMed ID: 19843683
[TBL] [Abstract][Full Text] [Related]
3. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
4. A BRCA1 mutation is not associated with increased indicators of oxidative stress.
Kotsopoulos J; Shen H; Rao AV; Poll A; Ainsworth P; Fleshner N; Narod SA
Clin Breast Cancer; 2008 Dec; 8(6):506-10. PubMed ID: 19073505
[TBL] [Abstract][Full Text] [Related]
5. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
Rothfuss A; Schütz P; Bochum S; Volm T; Eberhardt E; Kreienberg R; Vogel W; Speit G
Cancer Res; 2000 Jan; 60(2):390-4. PubMed ID: 10667592
[TBL] [Abstract][Full Text] [Related]
6. High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
Jernström H; Borg K; Olsson H
Mol Genet Metab; 2005; 86(1-2):320-7. PubMed ID: 16084122
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori infection is associated with oxidatively damaged DNA in human leukocytes and decreased level of urinary 8-oxo-7,8-dihydroguanine.
Siomek A; Rytarowska A; Szaflarska-Poplawska A; Gackowski D; Rozalski R; Dziaman T; Czerwionka-Szaflarska M; Olinski R
Carcinogenesis; 2006 Mar; 27(3):405-8. PubMed ID: 16219635
[TBL] [Abstract][Full Text] [Related]
8. Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age.
Tea MK; Weghofer A; Wagner K; Singer CF
Maturitas; 2013 Jun; 75(2):148-51. PubMed ID: 23528734
[TBL] [Abstract][Full Text] [Related]
9. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
10. Association between 8-oxo-7,8-dihydro-2'-deoxyguanosine excretion and risk of postmenopausal breast cancer: nested case-control study.
Loft S; Olsen A; Møller P; Poulsen HE; Tjønneland A
Cancer Epidemiol Biomarkers Prev; 2013 Jul; 22(7):1289-96. PubMed ID: 23658396
[TBL] [Abstract][Full Text] [Related]
11. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
12. Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5'-Cyclopurine-2'-deoxynucleosides and 8-hydroxy-2'-deoxyguanosine.
Rodriguez H; Jaruga P; Leber D; Nyaga SG; Evans MK; Dizdaroglu M
Biochemistry; 2007 Mar; 46(9):2488-96. PubMed ID: 17288454
[TBL] [Abstract][Full Text] [Related]
13. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
14. Small field radiotherapy of head and neck cancer patients is responsible for oxidatively damaged DNA/oxidative stress on the level of a whole organism.
Roszkowski K; Gackowski D; Rozalski R; Dziaman T; Siomek A; Guz J; Szpila A; Foksinski M; Olinski R
Int J Cancer; 2008 Oct; 123(8):1964-7. PubMed ID: 18688851
[TBL] [Abstract][Full Text] [Related]
15. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
16. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
17. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
18. [Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy].
Levanat S; Cvok ML
Lijec Vjesn; 2010; 132(1-2):34-7. PubMed ID: 20359158
[TBL] [Abstract][Full Text] [Related]
19. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
Hughes DJ; Ginolhac SM; Coupier I; Barjhoux L; Gaborieau V; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Sobol H; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Yannoukakos D; Mazoyer S; Lynch HT; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
Int J Cancer; 2005 Nov; 117(2):230-3. PubMed ID: 15900600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
